Why Semaglutide and Tirzepatide Get So Much Attention
GLP-1 receptor agonists affect pathways involved in appetite, satiety and gastric emptying. Semaglutide acts on the GLP-1 receptor, while tirzepatide acts on both GIP and GLP-1 receptors. Specific branded formulations have been studied in large randomized clinical trials and have FDA-approved indications for chronic weight management in eligible patients.
That does not mean every product containing those active ingredients is FDA-approved. Compounded medications are not FDA-approved and are not reviewed by the FDA before marketing for safety, effectiveness or quality.
Two Clinician-Guided Options to Compare
Tirzepatide
A dual-receptor medication discussed with eligible patients as part of clinician-guided weight-management care.
- Medical evaluation required
- Provider determines eligibility and dosing
- Telehealth-based pathway available through Vea
- Compounded versions are not FDA-approved
Semaglutide
A GLP-1 medication with extensive clinical research in specific FDA-approved branded formulations for eligible patients.
- Licensed-provider review required
- Individual medical history matters
- Telehealth-based pathway available through Vea
- Compounded versions are not FDA-approved
Affiliate relationship: The buttons above lead to Vea Health using affiliate tracking associated with BestPeptidesForWeightLoss.org. Vea states that provider approval is required. Treatment decisions are made by licensed clinicians.
What Does the Evaluation Process Look Like?
- Complete an intake.
Provide relevant health history, goals, medications and other requested information. - Licensed clinician review.
A provider determines whether treatment is medically appropriate for you. A prescription is not guaranteed. - Follow the prescribed plan.
If prescribed, treatment and follow-up should be based on the clinician's instructions rather than self-directed dosing.
Semaglutide vs. Tirzepatide at a Glance
| Topic | Semaglutide | Tirzepatide |
|---|---|---|
| Primary pathway | GLP-1 receptor agonism | GIP + GLP-1 receptor agonism |
| Weight-management evidence | Extensive randomized-trial evidence for specific branded products | Extensive randomized-trial evidence for specific branded products |
| Prescription required | Yes | Yes |
| Compounded versions FDA-approved? | No | No |
What About “Microdosing”?
Some telehealth programs market lower-dose or “microdosing” approaches. Evidence for GLP-1 microdosing as a distinct weight-loss strategy is less established than the evidence supporting labeled regimens of FDA-approved products. The appropriate formulation and dose should be determined by a licensed clinician.
Tirzepatide Microdosing
Explore Vea's clinician-guided pathway and discuss the evidence, formulation and dosing rationale with the treating provider.
Explore Tirzepatide Microdosing →Semaglutide Microdosing
Explore Vea's clinician-guided pathway and ask how a lower-dose approach compares with established treatment regimens.
Explore Semaglutide Microdosing →Questions Worth Asking Before You Choose a Provider
Ask who will review your medical history, what exact product may be prescribed, whether the medication is FDA-approved or compounded, which pharmacy dispenses it, how follow-up works, what side effects require medical attention, and what the total recurring cost includes.
Ready to Compare Your Options?
If you want to explore a clinician-guided program, review the available options and complete a medical evaluation. Eligibility and prescribing decisions are determined by the treating provider.
Frequently Asked Questions
Are compounded semaglutide or tirzepatide products FDA-approved?
No. Compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness or quality.
Is compounded medication the same as an FDA-approved generic?
No. FDA-approved generic drugs must meet FDA requirements. A compounded drug should not be represented as an FDA-approved generic equivalent.
Do I need a prescription?
Semaglutide and tirzepatide are prescription medications. Legitimate treatment requires evaluation and prescribing by an appropriately licensed clinician.
- U.S. FDA — Drug Compounding and Drug Shortages
- U.S. FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- FDA Drugs@FDA — Approved labeling and drug information
Editorial note: This page distinguishes evidence for FDA-approved branded products from compounded medication and avoids treating limited-evidence peptide therapies as equivalent to approved GLP-1 weight-management medicines.